GlassScriptPhysician profile
John R Brownell
NPI 1861452633
$5,472.21
in general payments reported to CMS, 2019-2025
40 companies · $1,348 in 2025
The $1,348 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $533 · 2020: $200 · 2021: $480 · 2022: $529 · 2023: $1,079 · 2024: $1,303 · 2025: $1,348.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,730.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,730.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $833.74 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Pfizer INC. | $737.17 | 2019-2025 | |
| Abbvie INC. | $606.73 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $312.82 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $233.69 | 2019-2025 | Evenity, Prolia, Repatha |
| Otsuka America Pharmaceutical, INC. | $228.67 | 2022-2025 | Rexulti |
| Phathom Pharmaceuticals, INC. | $211.38 | 2024-2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $190.56 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Novartis Pharmaceuticals Corporation | $182.12 | 2019-2024 | |
| Abbott Laboratories | $177.62 | 2021-2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $167.52 | 2022-2025 | Jardiance, Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $140.83 | 2019-2024 | Shingrix, Trelegy Ellipta, Bexsero |
| Dexcom, INC. | $108.49 | 2019-2025 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $103.06 | 2022-2025 | Veozah |
| Esperion Therapeutics, INC. | $99.07 | 2021-2025 | Nexletol |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Brownell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.